Radiopharmaceuticals for bone malignancy therapy

Journal of Nuclear Medicine Technology

Volumn 26, Issue 2, 1998, Pages 80-86

  Atkins, Harold L ^a   Srivastava, Suresh C ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Cancer; Palliation from metastases to bone; Phosphorus 32; Radionuclide therapy of bone malignancies; Rhenium 186; Samarium 153; Strontium 89; Tin 117m

Indexed keywords

PENTETATE TIN SN 117M; PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; SAMARIUM 153; STRONTIUM 89; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BONE METASTASIS; HUMAN; REVIEW;

BONE AND BONES; BONE MARROW; BONE NEOPLASMS; HUMANS; PAIN; PALLIATIVE CARE; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT;

EID: 0031749867     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Pecher C. Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of bone cancer University of California publications in pharmacology 1942;12:117-149.
2. Friedell HL, Storaasli JP. The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. Am J Roentgenol 1950;54:559-575.
3. Firusian N, Mellin P, Schmidt CG. Results of strontium-89 therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urology 1976;116:764-768.
4. Robinson RG. Radionuclides for the alleviation of bone pain in advanced malignancy Clin Oncol 1986;5.39-49.
5. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam therapy radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33-40.
6. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991;27:954-958.
7. Robinson RG, Spicer JA, Preston DF, et al. Treatment of metastatic bone pain with strontium-89. Nucl Med Biol 1987;14:219-222.
8. McEwan AJB. Radiopharmaceuticals for palliative treatment of painful bone metastases. New Perspec Cancer Diagn Management 1994;1:24-31.
9. Katin MJ, Salenius SA, Blitzer PH, et al. Hematologic effects of strontium-89 treatment for metastases to bone Proc Am Soc Clin Oncol 1993;3:12.
10. 32P labeled condensed phosphate. J Nucl Med 1960;1:1-13.
11. Edland RW. Testosterone potentiated radiophosphorus therapy of osseous metastases in prostatic cancer. Am J Roentgenol 1974;120:678-683.
12. Maxfield JR Jr, Maxfieid JGS, Maxfield WS. The use of radioactive phosphorus and testosterone in metastatic bone lesions from breast and prostate. South Med J 1958;51:320-328.
13. Turner JH, Claringbold PG. A Phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediami-netetramethylene phosphonate. Eur J Cancer 1991;27:1084-1086.
14. Farhanghi M, Holmes RA, Volkert WA, et al. Samarium-153 EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992;33:1451-1458.
15. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate cancer, a Phase I/II trial J Nucl Med 1993;34:1839-1844.
16. 153Smethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997;33:1583-1591.
17. Maxon HR III, Schroder LE, Thomas SR, et al. Rhenium-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 1990;176:155-159.
18. de Klerk JM, van Dijk A, van het Schip AD, et al. Pharmacokinetics of rhenium-186 after administration of rhenium-186 HEDP to patients with bone metastases. J Nucl Med 1992;33:646-651.
19. Atkins HL, Mausner LF, Srivastava SC, et al. Biodisiribution of tin-117m(4+) DTPA for palliative therapy of painful osseous metastases. Radiology 1993;186:279-283.
20. Atkins HL, Mausner LF, Srivastava SC, et al. Tin-117m(4+) DTPA for palliation of pain from osseous metastases, a pilot study. J Nucl Med 1995, 36:725-729.
21. Krishnamurthy GT, Swailem FM, Snvastava SC, et al. Tin-117m(4+) DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain. J Nucl Med 1997;38:230-237.
22. Srivastava SC, Atkins HL, Krishnamurthy GT, et al Treatment of metastatic bone pain with tin-117m stannic DTPA: a Phase I/II clinical study. Clin Cancer Res 1998;4:61-68.
23. 186Re HEDP and other agents for bone pain therapy. In: Nicolini M, et al., eds. Fourth International Symposium on Technetium in Chemistry and Nuclear Medicine: 1994. Padova: SG Editoriali; 1994:287-292.
24. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized Phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Physics 1993;25:805-813.
25. Robinson RG, Blake GM, Preston DF, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone Radiographies 1989;9:271-281.
26. Fossä SD, Paus E, Lochoff M, et al. Strontium-89 in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes. Brit J Cancer 1992;66:177-180.
27. Carretta RF, Weiland, FL, Vande Streck PR, et al Five years of clinical experience with strontium-89 [Abstract]. Eur J Nucl Med 1994;21:S44.
28. de Klerk JM, van het Schip AD, Zonnenberg BA, et al. Phase I study of rhenium-186 HEDP in patients with bone metastases originating from breast cancer. J Nucl Med 1996;37:244-249.
29. Eary JF, Collins C, Stabin M, et al. Samarium-153 EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993;34:1031-1036.